SG11202007241WA - Nucleic acid antibody constructs for use against respiratory syncytial virus - Google Patents
Nucleic acid antibody constructs for use against respiratory syncytial virusInfo
- Publication number
- SG11202007241WA SG11202007241WA SG11202007241WA SG11202007241WA SG11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- respiratory syncytial
- syncytial virus
- antibody constructs
- use against
- Prior art date
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624320P | 2018-01-31 | 2018-01-31 | |
| US201862749580P | 2018-10-23 | 2018-10-23 | |
| PCT/US2019/015975 WO2019152600A1 (en) | 2018-01-31 | 2019-01-31 | Nucleic acid antibody constructs for use against respiratory syncytial virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007241WA true SG11202007241WA (en) | 2020-08-28 |
Family
ID=67478343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007241WA SG11202007241WA (en) | 2018-01-31 | 2019-01-31 | Nucleic acid antibody constructs for use against respiratory syncytial virus |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210047390A1 (en) |
| EP (1) | EP3746474A4 (en) |
| JP (1) | JP2021512600A (en) |
| KR (1) | KR20200140799A (en) |
| CN (1) | CN111936513A (en) |
| AU (1) | AU2019215006A1 (en) |
| BR (1) | BR112020015588A2 (en) |
| CA (1) | CA3089717A1 (en) |
| MX (1) | MX2020008062A (en) |
| SG (1) | SG11202007241WA (en) |
| WO (1) | WO2019152600A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230111264A (en) * | 2016-11-07 | 2023-07-25 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | Dna antibody constructs for use against lyme disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0853487T3 (en) * | 1995-09-18 | 2000-10-23 | Us Health | Neutralizing monoclonal antibodies against respiratory syncytial virus |
| JP2005524389A (en) * | 2001-11-26 | 2005-08-18 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Enhanced electrical gene transfer of nucleic acid molecules into host tissues |
| GB0306618D0 (en) * | 2003-03-22 | 2003-04-30 | Univ Newcastle | Antibody |
| JP5734985B2 (en) * | 2009-09-17 | 2015-06-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ | Stable co-formulations of hyaluronidase and immunoglobulin and methods for their use |
| US8568726B2 (en) * | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| NZ718973A (en) * | 2010-07-09 | 2019-01-25 | Janssen Vaccines & Prevention Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| TWI659968B (en) * | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
| SG11201604719WA (en) * | 2013-12-13 | 2016-07-28 | Univ Pennsylvania | Dna antibody constructs and method of using same |
| EP4353316A2 (en) * | 2014-01-15 | 2024-04-17 | Medimmune Limited | Rsv-specific antibodies and functional parts thereof |
| CN107847588B (en) * | 2015-05-20 | 2021-12-28 | 免疫功坊股份有限公司 | Molecular construct with targeting and effector moieties and uses thereof |
| JO3555B1 (en) * | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
| EA201892525A1 (en) * | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | DNA ANTIBODY DESIGNS FOR USE AGAINST PSEUDOMONAS AERUGINOSA |
-
2019
- 2019-01-31 CA CA3089717A patent/CA3089717A1/en active Pending
- 2019-01-31 CN CN201980023801.0A patent/CN111936513A/en active Pending
- 2019-01-31 SG SG11202007241WA patent/SG11202007241WA/en unknown
- 2019-01-31 BR BR112020015588-8A patent/BR112020015588A2/en unknown
- 2019-01-31 EP EP19748286.2A patent/EP3746474A4/en active Pending
- 2019-01-31 US US16/966,506 patent/US20210047390A1/en active Pending
- 2019-01-31 MX MX2020008062A patent/MX2020008062A/en unknown
- 2019-01-31 JP JP2020541760A patent/JP2021512600A/en active Pending
- 2019-01-31 WO PCT/US2019/015975 patent/WO2019152600A1/en unknown
- 2019-01-31 KR KR1020207025149A patent/KR20200140799A/en active Search and Examination
- 2019-01-31 AU AU2019215006A patent/AU2019215006A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3746474A1 (en) | 2020-12-09 |
| CA3089717A1 (en) | 2019-08-08 |
| KR20200140799A (en) | 2020-12-16 |
| EP3746474A4 (en) | 2021-12-15 |
| BR112020015588A2 (en) | 2021-01-05 |
| WO2019152600A1 (en) | 2019-08-08 |
| US20210047390A1 (en) | 2021-02-18 |
| AU2019215006A1 (en) | 2020-09-17 |
| CN111936513A (en) | 2020-11-13 |
| MX2020008062A (en) | 2020-12-03 |
| JP2021512600A (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254950A1 (en) | Antibody neutralizing human respiratory syncytial virus | |
| EP3551193A4 (en) | Respiratory virus nucleic acid vaccines | |
| EP3595713A4 (en) | Respiratory syncytial virus vaccine | |
| IL258831A (en) | Respiratory syncytial virus vaccine | |
| EP3385278A4 (en) | Full human antibody against respiratory syncytial virus | |
| ZA201800938B (en) | Monoclonal antibodies specifically for phosphoprotein of the human respiratory syncytial virus and the methods of use | |
| IL277472A (en) | Nucleic acid molecules for pseudouridylation | |
| IL278061A (en) | Anti-ror antibody constructs | |
| EP3621640A4 (en) | Optimized nucleic acid antibody constructs | |
| PT2950886T (en) | Respiratory syncytial virus f protein epitopes | |
| EP3515482A4 (en) | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus | |
| HK1246781A1 (en) | Respiratory syncytial virus inhibitors | |
| IL275910A (en) | Methods for analyzing viral nucleic acid | |
| ZA201800940B (en) | Use of il-3, il-33, and il-12p40 for characterization of the respiratory infections by syncytial respiratory virus | |
| GB201812474D0 (en) | Nucleic acid construct | |
| EP3601334A4 (en) | Dna antibody constructs for use against hiv | |
| IL275296A (en) | Epstein-barr virus antigen constructs | |
| SG11202007241WA (en) | Nucleic acid antibody constructs for use against respiratory syncytial virus | |
| SG11202100713VA (en) | Depleting unwanted rna species | |
| EP3277707A4 (en) | Antibodies against infectious diseases | |
| HK1257223A1 (en) | Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein | |
| SG10202011021XA (en) | Dna monoclonal antibodies targeting influenza virus | |
| SG11201704201VA (en) | Catalyst and preparation method thereof, and method for preparing isobutylene by applying the same | |
| EP3548054A4 (en) | Dna antibody constructs for use against ebola virus | |
| EP3383428A4 (en) | Respiratory syncytial virus vaccine |